Hostname: page-component-7b7567c8c-tnzcf Total loading time: 0 Render date: 2026-11-15T01:52:12.676Z Has data issue: false hasContentIssue false
  • English
  • Français

Chorea

Published online by Cambridge University Press:  05 January 2016

Harold L. Klawans
Harold L. Klawans*
Affiliation:
Department of Neurological Sciences, Rush-Presbyterian St, Lukes Medical Center, Chicago
*
Department of Neurological Sciences, Rush-Presbyterian St, Lukes Medical Center, 1725 W. Harrison St., Chicago, IL., U.S.A. 60612
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

A variety of neurotransmitters have been implicated in the pathophysiology of chorea as exemplified by Huntington's chorea. These include dopamine, serotonin, acetylcholine, GABA and a variety of neuropeptides including substance P and somatostatin. Despite biochemical data that suggests that alterations in other neurotransmitters may be of greater significance, pharmacologic data still supports a major role of dopamine in the actual clinical manifestation of chorea.

Information

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 14 , Issue S3 , August 1987, pp. 536 - 540
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

REFERENCES

1.Lakke, PWF.Classification of extrapyramidal disorders. J Neurol Sci 1981: 51: 311–327.CrossRefGoogle Scholar
2.Klawans, HL.A pharmacologic analysis of Huntington’s chorea. Eur Neurol 1970:4: 148–163.CrossRefGoogle ScholarPubMed
3.Klawans, HL.The Pharmacology of Extrapyramidal Movement Disorders. S. Karger, Basel. 1973.Google ScholarPubMed
4.Bird, ED.Iversen, LL.Huntington’schorea. Brain 1974:97:457–472.CrossRefGoogle Scholar
5.van Rossum, JM.The significance of dopamine receptor blockade for the action of neuroleptic drugs. In: Brill, H.Cole, JO.Deniker, P, Hippius, H, and Bradley, PB eds., Neuro-Psychopharmacology. Proceedings of the 5th International Congress of the Collegium Internationale Neuropsychopharmacologicum, Washington. D.C.. March, 1966. International Congress Series No. 1966: 129: 166.Google Scholar
6.Birkmayer, W.The alpha-methyl-p-tyrosine effect in extrapyramidal disorders. Wien Klin Wochenschr 1969: 81: 10–12.Google Scholar
7.Klawans, HL.Weiner, WJ.The pharmacology of choreatic move-ment disorders. Prog Neurobiol 1975; 1–32.Google Scholar
8.Klawans, HL, Paulson, GW, Ringel, SP, Barbeau, A.Use of 1-dopa in the detection of presymptomatic Huntington’s chorea. ? Engl J Med 1972; 286: 1332–1334.CrossRefGoogle Scholar
9.Klawans, HL, Goetz, CG, Perlik, S.Presymptomatic and early detec-tion in Huntington’s disease. Ann Neurol 1980; 8: 343–347.CrossRefGoogle Scholar
10.Klawans, HL, Rubovits, R.Central cholinergic-anticholinergic antag-onism in Huntington’s chorea. Neurology 1972; 22: 107–116.CrossRefGoogle ScholarPubMed
11.Aquilonius, SM, Eckemas, SA.Choline therapy in Huntington’s chorea. Neurology 1977: 27: 887–889.CrossRefGoogle Scholar
12.Aquilonius, SM.On the synthesis, release and function of acetyl-choline in the central nervous system. Ph.D. dissertation, Univeristy of Uppsala.Google Scholar
13.Mcgeer, PL, Mcgeer, EG, Fibiger, HC.Choline acetylase and glutamic acid decarboxylase in Huntington’s chorea. Neurology 1975:23: 912–917.CrossRefGoogle Scholar
14.Hiley, CR, Bird, ED.Decreased muscarinic receptor concentration in post-mortem brain in Huntington’s chorea. Brain Res 1974; 80: 355–355.CrossRefGoogle ScholarPubMed
15.Aquilonius, SM, Sjostrom, R.Cholinergic and dopaminergic mecha-nisms in Huntington’s chorea. Life Sci 1971; 10: 405–414.CrossRefGoogle Scholar
16.Growdon, JH, Cohen, EL, Wurtman, RJ.Huntington’s disease: clinical and chemical effects of choline administration. Ann Neurol 1977; 1: 418–422.CrossRefGoogle ScholarPubMed
17.Tarsy, D.Leopold, N, Sax, DS.Physostigmine in choreiform move-ment disorders. Neurology 1974; 24: 28–33.CrossRefGoogle Scholar
18.Chase, TN, Watanabe, AM, Brodie, HKH, Donnelly, EF.Huntington’s chorea: Effect of serotonin depletion. Arch Neurol 1972; 26: 282–284.CrossRefGoogle ScholarPubMed
19.Perry, T, Hansen, S.Kloster, M.Huntington’s chorea: Deficiency of gamma amino butyric acid. New Engl J Med 1973; 288: 337–342.CrossRefGoogle Scholar
20.Barr, AN, Heinze, W, Mendoza, JE, Perlik, S.Long term treatment of Huntington’s disease with 1-glutamate and pyridoxine. Neurology 1978; 18: 1280–1282.CrossRefGoogle Scholar
21.Shoulson, I, Chase, TN, Roberts, E.Huntington’s disease treatment with imidazole-4-acetic acid. ? Engl J Med 1975; 293: 504–505.Google ScholarPubMed
22.Shoulson, I, Kartzinel, R, Chase, TN.Huntington’s disease: Treat-ment with dipropylacetic acid and GABA. Neurology 1976; 26: 61–63.CrossRefGoogle Scholar
23.Perry, T, Wright, J, Hansen, S, Macleod, P.Isoniazid therapy of Huntington’s disease. Neurology 1979; 29: 370–375.CrossRefGoogle Scholar
24.Perry, TLWright, JM, Hansen, S, et al. A double-blind clinical trial of isoniazid in Huntington’s disease. Neurology 1982; 32:354–358.CrossRefGoogle Scholar
25.Perry, TL, Wright, JM, Hansen, S, et al. Failure of aminoxyacetic acid therapy in Huntington’s disease. Neurology 1980; 30:772–775.CrossRefGoogle Scholar
26.Tell, G, Böhlen, P, Schechter, PJ, et al. Treatment of Huntington’s disease with -acetylenic GABA, an irreversible inhibitor of G ABA-transminase: increased CSF GABA and homocarnosine without clinical amelioration. Neurology 1981; 31: 207–211.CrossRefGoogle Scholar
27.Scigliano, G, Giavannini, P, Girotti, F, et al. Gamma-vinyl GABA treatment of Huntington’s disease. Neurology 1984; 34: 94–96.CrossRefGoogle ScholarPubMed
28.Kanazawa, I, Bird, ED, O’Connell, R, Powell, D.Evidence for a decrease in substance ? content of substantia nigra in Huntington’s chorea. Brain Res 1977; 120: 387–392.CrossRefGoogle ScholarPubMed
29.Kanazawa, I, Bird, ED, Gale, JS, et al. Substance P: decrease in substantia nigra and globus pallidus in Huntington’s disease. In: Chase, TN, Wexler, NS, Barbeau, A (eds.), Advances in Neurology, Vol 23, Huntington’s Disease, New York, Raven Press, 1979, 495–504.Google Scholar
30.Kanazawa, I.Clinical pathophysiology of basal ganglia disease. In: Winken, PJ, Bruyn, GW, Klawans, HL (eds.). Handbook of Clinical Neurology, in press.Google Scholar
31.Aronin, N, Cooper, PR, Lorens, LF, et al. Somatostatin is increased in the basal ganglia in Huntington’s disease. Ann Neurol 1983; 13: 519–526.CrossRefGoogle Scholar
32.Marshall, PE, Landis, DM.Huntington’s disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes. Brain Res 1985; 329: 71–82.CrossRefGoogle ScholarPubMed
33.Shults, C, Steardo, L, Barone, P, et al. Huntington’s disease: Effect of cysteamine, a somatostatin-depleting agent. Neurology 1986; 36: 1099–1102.CrossRefGoogle ScholarPubMed